Document Type : Review Article


Department of Personalized and Molecular Medicine, Era University, Lucknow-226003-india


Pharmacogenomics is the application of genetic and other omics data to specific medication selection and application for avoiding adverse drug reactions (ADR) and increasing drug potency. Pharmacists are playing an increasingly important role in optimizing medicine usage based on genetic testing results. Effect elucidation, genotype-guided medication and modification, medication asset, adverse reaction monitoring, and patient education are all tasks performed by pharmacists. Microbial invasion leads to infectious diseases, which have afflicted mankind from the early era, and is still impacting the health and one of the major causes of morbidity as well as mortality in the society. The response to therapy and the prognosis of an illness are also influenced by an individual’s genetic makeup. The data retrieved by genome sequencing of pathogen and humans is one further step forward in examining host-parasite interactions. Consideration of microbial pathogenicity factors, host genetic makeup, and the genetic mechanism involved in disease pathogenesis has paved the way for novel molecular approaches for medications, disease markers, and vaccinations to be discovered. The regulatory approval of amplification tests that are comparable or patronizing to existing gold standard procedures is now assisting the advancement of molecular diagnostics for infectious diseases. Progress in genetics and computation is altering the scale at which biological systems are depicted, and researchers may now expect a precision-focused variety in how they prepare for and respond to infectious diseases. This review will look at the origins and evolution of pharmacogenomics, as well as some of the controversies surrounding its therapeutic applications.


1.Weinshilboum RM, Wang L. Pharmacogenetics and Pharmacogenomics: Development, science, and translation. Annual Review of Genomics and Human Genetics. 2006; 7: 223-245.
2.Wang L, McLeod H L, Weinshilboum  RM. Genomics and drug response. New England Journal of Medicine. 2011; 364(12):1144-1153.
3.Giacomini KM, Yee SW, Ratain MJ, Weinshilboum RM, Kamatani N, et al. Pharmacogenomics and patient care: one size does not fit all. Science translational medicine. 2012;4(153):153ps18.
4.Hamburg M, Collins FS. The path to Personalized Medicine, New England Journal of Medicine. 2010;363(4):301-304.
5.Antony PM, Balling R, lassis N. From systems biology to systems biomedicine. Current Opinion in Biotechnology. 2012; 23(4):604-608.
6.Roy CR and Mocarski, ES, Pathogen subversion of cell-intrinsic innate immunity. Nature immunology. 2007;8(11):1179-1187.
7.Boutros M. and Ahringer J, The art and design of genetic screens: RNA interference. Nature Reviews Genetics. 2008;9 (7):554-566.
8.Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda, SK. et. al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nature methods. 2006; 3(10):777-779.
9.Koch R, the Nobel Prize, and the Ongoing Threat of Tuberculosis SHE Kaufmann. New Eng. J. Med. 2005;353(23):2423-2426.
10.Marquet S. and Schur E. Genetics of susceptibility to infectious diseases: Tuberculosis and Leprosy as examples. Drug Metabolism and Disposition. 2001;29(4):479-483.
11.Tyler-Smith C, Yang H, Landweber LF, Dunham I, et al. Where next for genetics and genomics? PLoS Biology. 2015;13(7):e1002216.
12.Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. 2013;155(1):27-38.
13.Mardis ER :Next-generation sequencing platforms. Annual review of analytical chemistry.  2013:287-303.
14.Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, Ramachandran S, et al. Worldwide human relationships inferred from genome-wide patterns of variation science. 2008;319(5866):1100-1104.
15.Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, Feldman MW. Genetic structure of human populations science. 2022; 298(5602):2381-2385.
16.Shriner D, Tekola-Ayele, F, Adeyemo A. Rotimi CN. Genome-wide genotype and sequence-based reconstruction of the 140,000 year history of modern human ancestry. Scientific reports. 2014; 4(1):1-9.
17.Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Therapeutic advances in medical oncology. 2017;9(8):519-531.
18.Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS. Prostate cancer screening in a new era of genetics. Clinical Genitourinary Cancer. 2017;15(6):625-628.
19.Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecologic oncology. 2017;146(2):399-404.
20.Yan B, Hu Y, Ban KH, Tiang Z, Ng C, Lee J, Tan W, et al 2017. Single-cell genomic profiling of acute myeloid leukemia for clinical use: A pilot study. Oncology letters. 2017;13(3) 2017:1625-1630.
21.Pannone L, Bocchinfuso G, Flex E., Rossi C, Baldassarre G, et. al, Structural, functional, and clinical characterization of a novel PTPN11 mutation cluster underlying Noonan syndrome. Human mutation. 2017;38(4):451-459.
22.Das K, Taguri M, Imamura H, Sugimoto N, Nishikawa K, Yoshida K, Tan P, Tsuburaya, A. Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. Cancer letters. 2018;412:08-215.
23.Mohanty A, Sandoval N, Das M, Pillai R, Chen L, et. al. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016;7(45):73558.
24.Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, et al. Pharmacogenetic analysis of the UK MRC MAGIC trial: association of polymorphisms with toxicity and survival in patients treated with perioperative ECF chemotherapy 2017.
25.Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. In Mayo Clinic Proceedings. 2017;92(11):1711-1722.
26.Chia S, Low JL, Zhang X, Kwang XL, Chong FT et. al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nature communications. 2017;8(1):1-12.
27.Venter JC, Adams M.D, Myers EW, Li PW, Mural RJ, et al. The sequence of the human genome. Science.  2001;291(5507):1304-1351.
28.Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC. Initial sequencing and analysis of the human genome  2001.
29.Collins F. Completion of the first survey of the entire human genome project. National Human Genome Research (accessed 2002).
30.Institute of Genomic Research. TIGR microbial database. mdbcomplete.html (accessed 2002 Apr 19).
31.Tyler-Smith C, Yang H, Landweber LF, Dunham I, Knoppers BM, Donnelly P, Mardis ER, Snyder M. and McVean, G. Where next for genetics and genomics?. PLoS biology. 2015;13(7):1002216.
32.Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER, 2013. The next-generation sequencing revolution and its impact on genomics. Cell. 2013;155(1):27-38.
33.Mardis ER. Next-generation sequencing platforms. Annual review of analytical chemistry. 2013;6:287-303.
34.Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, et. al. Worldwide human relationships inferred from genome-wide patterns of variation. Science. 2008;319(5866):1100-1104.
35.Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA and Feldman MW. Genetic structure of human populations. Science. 2002;298(5602):2381-2385.
36.Shriner D, Tekola-Ayele F, Adeyemo A, Rotimi CN. Genome-wide genotype and sequence-based reconstruction of the 140,000 year history of modern human ancestry. Scientific reports. 2014;4(1):1-9.
37.Rowell JL, Dowling F, Yu W, Yesupriya A, Zhang L, Gwinn M. Trends in population-based studies of human genetics in infectious diseases. PLoS One. 2012;7(2):25431.
38.Relling MV, Klein T. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clinical Pharmacology & Therapeutics. 2011;89(3);464-467.
39.Muenke M. Individualized genomics and the future of translational medicine. Molecular genetics & genomic medicine. 2013;1(1):1.
40.Ginsburg GS and Willard HF. Genomic and personalized medicine: foundations and applications. Translational research. 2009;154(6):277-287.
41.Adeyemo A. and Rotimi C. What does genomic medicine mean for diverse populations? Molecular genetics & genomic medicine. 2014;2(1):3.
42.Goodwin, S., McPherson, J.D. and McCombie, W.R., 2016. Coming of age: ten years of next-generation sequencing technologies. Nature Reviews Genetics. 2016;17(6):333-351.
43.MacCannell D. Platforms and analytical tools used in nucleic acid sequence-based microbial genotyping procedures. Microbiology spectrum. 2019;7(1):7-1.
44.DNA sequencing costs: data. Bethesda, MD: National Human Genomics Research Institute, 2019 (https://www.genome .gov/27541954/dna-sequencing-costs-data/).
45.Köser CU, Ellington MJ, Cartwright EJ, Gillespie SH, Brown, et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology.
46.Gwinn M, MacCannell D. and Armstrong GL. Next-generation sequencing of infectious pathogens, Jama. 2019;321:893-894.
47.Centers for Disease Control and Prevention (2013) Antibiotic resistance threats in the United States, 2013. Available at threat-report-2013/index.html. Accessed August 1, 2018.
48.Hooper DC. Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clinical infectious diseases. 2001;32(1):S9-S15.
49.Louie L, Matsumura SO, Choi E, Louie M, Simor AE. Evaluation of three rapid methods for detection of methicillin resistance in Staphylococcus Aureus. Journal of clinical microbiology. 2000;38(6):2170-2173.
50.Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65. 
51.Edwards‐Smith, CJ, Jonsson JR, Purdie DM, Bansal A, et al. Interleukin‐10 promoter polymorphism predicts initial response of chronic Hepatitis C to interferon alfa, Hepatology. 1999;30(2):526-530.
52.Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma Gondii vaccine. The Journal of Immunology. 1991;146(1):286-292.
53.Gazzinelli RT, Hakim FT, Hieny S, Shearer GM, Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma Gondii vaccine. The Journal of Immunology. 1991;146(1):286-292.
54.Sher ALAN, Coffman RL, Hieny SARA, Cheever AW. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma Mansoni in the mouse. The Journal of Immunology. 1990;145(11)L:3911-3916.
55.Tang YW, Graham BS. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with Respiratory Syncytial Virus. The Journal of Clinical Investigation. 1994;94(5):1953-1958.
56.Paul WE and Seder RA. Lymphocyte responses and cytokines. Cell. 1994;76(2):241-251.
57.Poland GA. Immunogenetic mechanisms of antibody response to measles vaccine: the role of the HLA genes. Vaccine. 1999;17(13-14):1719-1725.
58.Poland GA, Jacobson RM, Schaid D, Moore SB, Jacobsen SJ. The association between HLA class I alleles and measles vaccine-induced antibody response: Evidence of a Significant Association. Vaccine. 1998;16(19):1869-1871.
59.Hayney MS, Poland GA, Jacobson RM, Rabe D, et al. Relationship of HLA-DQAI alleles and humoral antibody following measles vaccination. International Journal of Infectious Diseases. 1998;2(3):143-146.
60.Hayne, MS, Poland GA, Jacobson RM, Schaid DJ, Lipsky JJ. The influence of the HLA-DRB1* 13 allele on measles vaccine response. Journal of investigative medicine: the official publication of the American Federation for Clinical Research. 1996;44(5):261-263.
61.Guthrie JL, Gardy JL. A brief primer on genomic epidemiology: lessons learned from Mycobacterium tuberculosis. Annals of the New York Academy of Sciences. 2017;1388(1):59-77.
62.Althomsons SP, Hill AN, Harrist AV, France AM, Powell KM, Posey JE, Cowan LS and Navin TR. Statistical method to detect Tuberculosis outbreaks among endemic clusters in a low-incidence setting. Emerging infectious diseases. 2018;24(3):573.
63.Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G et. al. Whole-genome sequencing to delineate Mycobacterium Tuberculosis outbreaks: a Retrospective Observational Study. The Lancet Infectious Diseases. 2013;13(2):137-146.
64.Gardy JL, Johnston JC, Sui SJH, Cook VJ, Shah L, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. New England Journal of Medicine. 2011;364(8):730-739.
65.Guthrie JL, Delli Pizzi A, Roth D, Kong C, Jorgensen D, Rodrigues M  et. al. Genotyping and whole-genome sequencing to identify tuberculosis transmission to pediatric patients in British Columbia, Canada, 2005–2014. The Journal of infectious diseases. 2018;218(7):1155-1163.
66.Jajou R, de Neeling A, van Hunen R, de Vries G, et al. Correction: Epidemiological links between tuberculosis cases identified twice as efficiently by whole genome sequencing than conventional molecular typing: A population-based study. Plos one. 2018;13(5):0197556.
67.Guthrie JL, Strudwick L, Roberts B, Allen M, McFadzen J, et al. Whole genome sequencing for improved understanding of Mycobacterium Tuberculosis transmission in a remote circumpolar region. Epidemiology & Infection, 147.
68.Parvaresh L, Crighton T, Martinez E, Bustamante A, Chen S, Sintchenko V. Recurrence of tuberculosis in a low-incidence setting: a retrospective cross-sectional study augmented by whole genome sequencing. BMC infectious diseases. 2018;18(1):1-6.
69.Luo T, Yang C, Peng Y, Lu L, et al. Whole-genome sequencing to detect recent transmission of Mycobacterium tuberculosis in settings with a high burden of tuberculosis. Tuberculosis. 2014;94(4):434-440.
70.CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. New England Journal of Medicine. 2018;379(15):1403-1415.
71.Doyle RM, Burgess C, Williams R, Gorton R, Booth H. et al. Direct whole-genome sequencing of sputum accurately identifies drug-resistant Mycobacterium tuberculosis faster than MGIT culture sequencing. Journal of Clinical Microbiology. 2018;56(8):00666-18.
72.Shea J, Halse TA, Lapierre P, Shudt M, et al. Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium Tuberculosis in New York State. Journal of clinical microbiology. 2017;55(6):1871-1882.
73.Papaventsis D, Casali N, Kontsevaya I, Drobniewski F,et al. . Whole genome sequencing of Mycobacterium Tuberculosis for detection of drug resistance: a Systematic Review. Clinical Microbiology and Infection.  2017;23(2):61-68.
74.Dolinger DL, Colman RE, Engelthaler DM, Rodwell TC. Next-generation sequencing-based user-friendly platforms for drug-resistant tuberculosis diagnosis: a promise for the near future. International journal of mycobacteriology. 2016;5:S27-S28.
75.World Health Organization, 2018. World Malaria Day 2018” Ready to Beat Malaria”: key messages (No. WHO/CDS/GMP/2018.06). World Health Organization.
76.Kwiatkowski D. Malaria genomics: tracking a diverse and evolving parasite population. International health. 2015;7(2):82-84.
77.Miles A, Iqbal Z, Vauterin P, Pearson R, et al.  structural variation, and recombination drive genomic diversity in Plasmodium falciparum. Genome research.  2016;26(9):1288-1299.
78.Bopp SE, Manary MJ, Bright AT, Johnston GL, et al. Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS genetics. 2013;9(2):1003293.
79.Malaria Genomic Epidemiology Network. A novel locus of resistance to severe malaria in a region of ancient balancing selection.  Nature. 2015; 526, 253–257. 
80.Caro F, Ahyong V, Betegon M, DeRisi JL. Genome-wide regulatory dynamics of translation in the Plasmodium falciparum asexual blood stages.2014;3:04106.
81.Bunnik EM, Chung DWD, Hamilton M, Ponts N, et al. Polysome profiling reveals translational control of gene expression in the human malaria parasite Plasmodium Falciparum. Genome biology. 2013;14(11):1-18.
82.Ahn BE, Cha J, Lee EJ, Han AR, et al. Nur, a nickel‐responsive regulator of the Fur family, regulates superoxide dismutases and nickel transport in Streptomyces coelicolor. Molecular microbiology. 2006;59(6):1848-1858.
83.Yamagishi J, Natori A, Tolba ME, Mongan AE, et al. Interactive transcriptome analysis of malaria patients and infecting Plasmodium Falciparum. Genome Research. 2014;24(9):1433-1444.
84.Zhu L, Mok S, Imwong M, Jaidee A, et al. New insights into the Plasmodium Vivax transcriptome using RNA-Seq. Scientific reports. 2016;6(1):1-13.
85.WHO/Department of Control of Neglected Tropical Diseases (2016). Global programme to eliminate lymphatic filariasis: progress report, 2015. Wkly. Epidemiol. Rec. 39, 441–460.
86.Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. The Lancet. 2010;376(9747):1175-1185.
87.Boettger LM, Handsaker RE, Zody MC, McCarroll SA. Structural haplotypes and recent evolution of the human 17q21. 31 region. Nature genetics. 2012;44(8):881-885.
88.Cotton JA, Bennuru S, Grote A, Harsha B, et al. The genome of Onchocerca Volvulus, agent of river blindness. Nature microbiology. 2016;2(2):1-12.
89.Molehin AJ, Gobert GN, McMANUS DP. Serine protease inhibitors of parasitic helminths. Parasitology. 2012;139(6):681-695.
90.Cuenco KT, Halloran ME, Louis-Charles J, Lammie PJ. A family study of lymphedema of the leg in a lymphatic filariasis–endemic area. The American Journal of Tropical Medicine and Hygiene. 2004;70(2):180-184.
91.Chesnais CB, Sabbagh A, Pion SD, Missamou F, et al. Familial Aggregation and Heritability of Wuchereria Bancrofti infection. The Journal of Infectious Diseases. 2016;214(4):587-594.
92.Tekola Ayele F, Adeyemo A, Finan C, Hailu E, et al. HLA class II locus and susceptibility to Podoconiosis. New England Journal of Medicine. 2012;366(13):1200-1208.
93.Addiss DG. Global elimination of Lymphatic Filariasis: Addressing the Public Health Problem. PLoS Neglected Tropical Diseases. 2010;4(6):741.
94.Price EW. The association of endemic elephantiasis of the lower legs in East Africa with soil derived from volcanic rocks. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1976;70(4):288-295.
95.Davey G, Tekola F, Newport MJ. Podoconiosis: Non-infectious geochemical elephantiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101(12):1175-1180.